Sanofi, a global pharmaceutical giant, is making another major investment in Beijing Economic-Technological Development Area (Beijing E-Town). The company plans to invest approximately EUR 1 billion in building a new insulin production facility in Beijing E-Town, to meet the needs of diabetes patients in China. This will be Sanofi's fourth manufacturing and supply base in China and represents the company's largest single investment in the country.

The newly established insulin production base marks the first time a multinational pharmaceutical company has decided to set up a production facility for biopharmaceutical active pharmaceutical ingredients (APIs) in China. Once completed, the facility will primarily produce the biologic active substances of insulin to supply APIs for Sanofi's existing insulin formulation products at its Beijing plant.

Recently, global industrial leaders such as Eli Lilly, Pfizer, and Medtronic have also announced their plans to establish new R&D and innovation centers in Beijing E-Town. The area will continue optimizing its business environment, and foster an open and inclusive industrial ecosystem to support multinational companies in choosing to invest in Beijing E-Town. The aim is to draw up a new blueprint for the development of the pharmaceutical and healthcare industries in Beijing.

(Source: Beijing Economic-Technological Development Area)